Quabodepistat for tuberculosis, multidrug-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Oct 2025: Trial registered, NCT07209761
  2. 16 Oct 2025: Trial started, NCT07209761

The trials

NCT07209761: A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

State
Under way
Phase
Phase 3
People
532 planned
Started
16 Oct 2025
Primary completion
29 Sep 2028
Arms
BPaQM for fluoroquinolone-susceptible RR/MDR-TB, BPaQ for fluoroquinolone-resistant RR/MDR-TB
Results
None posted
  1. 7 Oct 2025: Trial registered
  2. 16 Oct 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.